Zelira Therapeutics Ltd has released a press release.
Publication of ZLT-L-007 IRB Approved Observational Study
Earlier from Zelira Therapeutics
- Zelira secures $1 Million At-the-Market Funding Facility
- Appendix 4D & FY25 Interim Financial Report
- Zelira receives $1,153,000 R&D Tax Incentive Scheme Refund